Health and wellness company begins selling mammography AI directly to consumers for $249
A health and wellness company has begun selling a key mammography artificial intelligence solution directly to consumers.
Austin, Texas-based Everlywell recently announced the nationwide rollout and commercial availability of Clairity Breast to its users. Founded in 2015, Everlywell sells lab testing kits and digital diagnostic solutions to patients, “transforming care” for some 60 million people.
The company said it is now offering Clairity Breast for $249 a pop, allowing women to upload their mammogram to the platform. Authorized by the Food and Drug Administration in 2025, the solution predicts patients’ five-year risk of developing breast cancer based on a routine screening.
"Women deserve clear answers about their health, and access to the most advanced tools in healthcare, not years from now, but today. That belief is why I built Everlywell, and it's why we're so proud to partner with Clairity Breast,” entrepreneur Julia Cheek, founder and CEO of Everlywell, said in a statement Oct. 1. “This partnership expands access to cutting-edge preventive care, and that means a woman can learn more about her future breast cancer risk from the mammogram she already gets and walk into her doctor's office with information she's never had before."
Paired with Everlywell’s nationwide reach, those involved believe the partnership will help give women more info about their health and risk of cancer. They note that about 85% of breast cancers occur in women with no family history of the disease.
Clairity was founded by founded in 2020 by radiologist Constance “Connie” Lehman, MD, PhD, a Harvard professor of radiology and former chief of breast imaging at Massachusetts General. Last year, its flagship product became the first AI-based tool to receive the FDA’s De Novo authorization for predicting breast cancer risk. It has scored additional wins since then, including updated National Comprehensive Cancer Network guidelines introducing the product as an option for identifying women at increased risk beginning at age 35.
The two companies note that Clairity Breast has had limited availability through health systems such as Beth Israel Deaconess Medical Center in Massachusetts and Invision Sally Jobe in Colorado. With the new distribution deal, patients across the U.S. with a qualifying recent mammogram from the past year can access the risk assessment tool via Everlywell’s platform. This includes review and ordering by a licensed provider in Everlywell’s affiliated clinician network and results reviewed and released with next steps.
“The information we need to understand a woman's breast cancer risk has been in her mammogram all along—we just haven't been able to interpret it until Clairity Breast. Now, it can also inform conversations with your healthcare provider about the best screening and risk reduction options for you,” Dr. Lehman said in the announcement.
The companies are encouraging individuals to share the results with their own providers to “inform her screening and risk reduction plan.” Clairity joins other cancer screening options in the Everlywell platform, including an at-home collection colon cancer screening kit and recently launched HPV self-exam option for cervical cancer screening.
STAT News also highlighted the new offering in a report published Thursday. It notes that this is part of a growing trend of preventive medicine products being consumerized online. However, physicians are expressing concern about the idea of putting the onus on individual patients to pay for a new test whose real-world impact has not yet been studied.
Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic.